Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/85883
Title: Midkine release during hemodialysis is predictive of hypervolemia and associates with excess (cardiovascular) mortality in patients with end-stage renal disease : a prospective study
Author(s): Brandt, SabineLook up in the Integrated Authority File of the German National Library
Fischer, AnjaLook up in the Integrated Authority File of the German National Library
Kreutze, Carla
Hempel, DorotheaLook up in the Integrated Authority File of the German National Library
Gorny, Xenia
Scurt, Florian GunnarLook up in the Integrated Authority File of the German National Library
Şalaru, Delia L.
Bartsch, Peter
Bernhardt, AnjaLook up in the Integrated Authority File of the German National Library
Bode-Böger, Stefanie M.
Girndt, MatthiasLook up in the Integrated Authority File of the German National Library
Fiedler, RomanLook up in the Integrated Authority File of the German National Library
Isermann, BerendLook up in the Integrated Authority File of the German National Library
Lindquist, Jonathan A.
Mertens, Peter ReneLook up in the Integrated Authority File of the German National Library
Issue Date: 2022
Type: Article
Language: English
Abstract: Background: In end-stage renal disease, a high cardiovascular risk profile and endothelial damage prevails. The heparin-binding growth factor midkine stimulates neo-angiogenesis in ischemic diseases, coordinates neutrophil influx, and raises blood pressure through stimulated angiotensin synthesis. Methods: We determined changes of midkine serum levels during hemodialysis sessions under the assumption that endothelial cell-derived midkine is released. Periprocedural differences (∆midkine) were calculated and correlated with cardiovacular biomarkers and fluid status (clinical assessment, V. cava collapse, comet tail phenomenon), cardiovascular morbidities, mortality rates. Blood was collected before and after dialysis from hemodialysis patients (n = 171; diabetes: n = 70; hypervolemia: n = 83; both: n = 32). Results: Baseline midkine levels were ~ fourfold elevated compared to healthy controls (n = 100). Further, on average a tenfold rise was detected during dialysis, the extent of which was partially related to non-fractionated heparin application (r2 = 0.17). Inter-individual differences were highly reproducible. Hypervolemic patients responded with a less than average rise in midkine levels during dialysis (p < 0.02), this difference became more obvious with co-existing diabetes (p < 0.001 for long dialysis-free interval) and was confirmed in an independently enrolled dialysis cohort (n = 88). In Kaplan Meier survival curves, low delta midkine levels correlated with cardiovascular/overall mortality rates, similar to elevated uPAR levels, whereas other markers (NTproANP, galectin, tenascin-C) were less predictive. Following intervention with successful fluid removal in hypervolemic dialysis patients to optimize fluid homeostasis, midkine values increased (p < 0.002), which was not observed in patients that failed to decrease weight. Conclusion_ Thus, for dialysis patients inadequate periprocedural midkine upregulation is linked with hypervolemia and associates with cardiovascular events.
URI: https://opendata.uni-halle.de//handle/1981185920/87836
http://dx.doi.org/10.25673/85883
Open Access: Open access publication
License: (CC BY 4.0) Creative Commons Attribution 4.0(CC BY 4.0) Creative Commons Attribution 4.0
Sponsor/Funder: Publikationsfonds MLU
Journal Title: International urology and nephrology
Publisher: Springer Science + Business Media B.V.
Publisher Place: Dordrecht [u.a.]
Original Publication: 10.1007/s11255-022-03141-4
Appears in Collections:Open Access Publikationen der MLU

Files in This Item:
File Description SizeFormat 
Brandt2022_Article_MidkineReleaseDuringHemodialys.pdf1.83 MBAdobe PDFThumbnail
View/Open